SCHEMBL9890716

SCHEMBL9890716

CNC(=O)Cc1ccccc1-c1cccc(Cl)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 6/20 0.62
CHRM3 P20309 3/20 0.62
KCNJ5 P48544 1/20 0.48
KCNJ3 P48549 1/20 0.48
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
HTR7 P34969 1/20 0.44
VEGFA P15692 1/20 0.44
FLT1 P17948 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44
EGLN3 Q9H6Z9 1/20 0.44
PLA2G1B P04054 1/20 0.43
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
NUDT1 P36639 1/20 0.43
ADORA1 P30542 1/20 0.42
SUCNR1 Q9BXA5 1/20 0.41
PTGER1 P34995 1/20 0.41
PTGER4 P35408 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890769 0.89 CHRM1 (0.50) CHRM1CHRM3KCNJ5KCNJ3HSP90AA1
SCHEMBL2394292 0.84 FFAR1 (0.47) CHRM1CHRM3HTR7PLA2G1BHTT
SCHEMBL9890714 0.84 CYP2C19 (0.49) CHRM1CHRM3HTR7SUCNR1
SCHEMBL2397419 0.83 KMT2A (0.51) CHRM1CHRM3L3MBTL1
SCHEMBL2393439 0.83 SMN1; SMN2 (0.46) CHRM1CHRM3HTR7HTTPTGER1
SCHEMBL9890735 0.83 CHRM1 (0.44) CHRM1CHRM3HTTL3MBTL1PTGER1
SCHEMBL9890642 0.82 CHRM1 (0.57) CHRM1CHRM3SUCNR1PTGER1PTGER4
SCHEMBL2393525 0.81 PTGDR2 (0.47) CHRM1CHRM3PLA2G1BHTTL3MBTL1
SCHEMBL9890728 0.81 FFAR1 (0.46) CHRM1CHRM3PLA2G1BHTTL3MBTL1
SCHEMBL2393760 0.81 CHRM1 (0.56) CHRM1CHRM3KCNJ5KCNJ3HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM1 340/4885CHRM3 298/4885KCNJ5 282/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CHRM1 340/4885CHRM3 298/4885KCNJ5 282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.